Journal article
Survival outcomes and prognostic factors in therapy-related Acute Myeloid Leukemia: A SEER database study, 2000-2020
Clinical lymphoma, myeloma and leukemia, Vol.24(11), pp.e827-e834.e1
11/2024
DOI: 10.1016/j.clml.2024.07.002
Abstract
With advances in therapeutics and longer survival across different cancer spectrums, the incidence of therapy-related acute myeloid leukemia (tAML) has continued to rise. This study aims to evaluate the trend of survival outcomes and their association with sociodemographic factors in tAML over the last 20 years.
We identified tAML patients between 2000 and 2020 from the Surveillance, Epidemiology, and End Results database. Patients were divided into four age groups: 18-39, 40-59, 60-69, and >= 70 years, and four diagnostic periods: 2000-2005, 2006-2010, 2011-2015, and 2016-2020. Overall survival (OS) was compared using Kaplan Meier and log-rank methods.
The 1-year (and 5-year) OS in patients with tAML was 59.3% (33.7%), 48.2% (24.8%), 37.2% (11.1%), and 32.9% (5.5%) in age groups 18-39, 40-59, 60-69, and >=70 years, respectively. The 1-year (and 5-year) OS based on the year of diagnosis was 20.9% (13.2%), 36.8% (15.2%), 41.9% (13.88%), and 40.4% (not reached) for 2000-2005, 2006-2010, 2011-2015, and 2016-2020 respectively. Among the youngest cohort aged 18-39 years, 1-year OS was 35.7%, 57.7%, 66.7%, and 59.6%, respectively, in four diagnostic periods, whereas 1-year OS was 10.5%, 23.9%, 32.2%, and 36.9%, respectively, in the oldest cohort aged >=70 years. Age, year of diagnosis, and geographic location were independent prognostic markers of OS.
Our study demonstrates a significant improvement in the 1-year OS of tAML patients over the last decade, but the long-term prognosis remains dismal. Older patients continue to show improved survival in recent years with the addition of newer intensive and non-intensive options.
We utilized the SEER database to evaluate the trend of survival outcomes and association with sociodemographic factors in therapy-related AML (tAML) over the last 20 years. The incidence of tAML has continued to rise between 2000-2020, directly related to newer advancements in cancer therapeutics. Despite a significant improvement in 1-year survival over the last decade, long-term prognosis remains dismal.
Details
- Title: Subtitle
- Survival outcomes and prognostic factors in therapy-related Acute Myeloid Leukemia: A SEER database study, 2000-2020
- Creators
- Utsav Joshi - Moffitt Cancer CenterUttam Bhetuwal - Rhode Island HospitalSumeet K Yadav - Mayo Clinic Health SystemPravash Budhathoki - Department of Internal Medicine, Bronxcare Health System, New York, NYSuman Gaire - Mount Sinai HospitalShiwani Sharma - National Academy of Medical SciencesChengu Niu - Rochester General HospitalSoon Khai Low - Medical College of WisconsinNiraj Neupane - Rochester General HospitalVishakha Agrawal - University of South FloridaBishesh Sharma Poudyal - Civil Service HospitalPrajwal Dhakal - University of Iowa
- Resource Type
- Journal article
- Publication Details
- Clinical lymphoma, myeloma and leukemia, Vol.24(11), pp.e827-e834.e1
- Publisher
- Elsevier Inc; DALLAS
- DOI
- 10.1016/j.clml.2024.07.002
- ISSN
- 2152-2650
- eISSN
- 2152-2669
- Language
- English
- Electronic publication date
- 07/2024
- Date published
- 11/2024
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984656556502771
Metrics
2 Record Views